Candida glabrata, Candida krusei, non-albicans Candida spp., and other fungal organisms in a sixty-bed national cancer center in 1989-1993: no association with the use of fluconazole.
During the 5-year period 1989-1993, the incidence of Candida krusei, and other non-albicans Candida spp., was analyzed in a 60-bed cancer department. The frequency of C. krusei, before fluconazole was introduced into therapeutic protocols in 1990, was 16.5%, and after introduction of fluconazole into prophylaxis in acute leukemia in 1991, the incidence of C. krusei was 12.7%. After 3 years of using this drug in therapy and prophylaxis, the incidence of C. krusei in 1993 was 14.8%, what was lower than before this drug was introduced in our country. 97.6% of all isolated fungi were yeasts and only 2.4% were molds. Among yeasts, the most frequently isolated pathogen was Candida albicans with 64.3% in 1989 and 74.2% in 1993. The next was C. krusei with 21.2% in 1992 and 16.5% in 1989, but 14.8% in 1993, and Candida tropicalis and Candida glabrata with 9.03% in 1989 and 2.7% in 1993. Among the molds, Aspergillus spp. was the most frequently isolated genus. Analyzing the etiology of mycologically proven fungal infections confirmed by positive blood cultures or biopsies, C. albicans and Aspergillus spp. were the most common causative organisms.
Kunová
A
A
Department of Microbiology, National Cancer Institute, Bratislava, Slovak Republic.
Trupl
J
J
Spánik
S
S
Drgona
L
L
Sufliarsky
J
J
Lacka
J
J
Studená
V
V
Hlavácová
E
E
Studená
M
M
Kukucková
E
E
D002173:Cancer Care Facilities; D002175:Candida / Q000145:classification / Q000187:drug effects*; D015725:Fluconazole / Q000494:pharmacology* / Q000627:therapeutic use; D005658:Fungi / Q000187:drug effects*; D006801:Humans; D015994:Incidence; D009181:Mycoses / Q000453:epidemiology / Q000382:microbiology* / Q000517:prevention & control; D012189:Retrospective Studies; D018154:Slovakia; D013045:Species Specificity; D015163:Superinfection / Q000382:microbiology
D015725:Fluconazole